0
0
May 4, 2026
A landmark study led by researchers at Johns Hopkins University and the University of California San Diego has revealed that the vast majority of Americans participating in the federal regulatory process support moving cannabis out of its most restrictive legal category. The findings, published in the journal Addiction, show that public sentiment has not only moved toward reclassification but frequently exceeds the federal government’s current reform efforts, with most respondents calling for an end to federal prohibition entirely.
The analysis arrived as a pivotal moment for U.S. drug policy. Following a 2024 proposal by the Drug Enforcement Administration (DEA) to move cannabis from Schedule I (drugs with no accepted medical use, like heroin) to Schedule III (drugs with moderate to low potential for dependence, like Tylenol with codeine), federal authorities officially began reclassifying state-licensed medical marijuana in April 2026. However, researchers found that 63.5% of the 42,913 public comments reviewed argued that this change does not go far enough.
AI-Assisted Analysis of Public Sentiment
To process the massive volume of public input, researchers utilized an artificial intelligence-assisted review validated against human coding. The dataset represents the largest collection of public input on federal cannabis policy to date.
The breakdown of the 42,913 comments revealed a clear mandate for change:
-
63.5% supported reform even more extensive than Schedule III (such as full descheduling).
-
28.9% supported the proposed move to Schedule III.
-
6.7% opposed any change to the current scheduling.
In total, 92.4% of commenters supported removing cannabis from Schedule I.
“The public record shows Americans want federal policy to go even further,” said senior author John W. Ayers, Ph.D., Vice Chief of Innovation at the UC San Diego School of Medicine. “When overwhelming support shows up in a public comment process that typically skews negative, it’s a strong indicator that the War on Drugs approach to cannabis has lost public credibility.”
Arguments for Reform: Medicine, Economy, and Justice
Supporters of reclassification frequently cited the therapeutic benefits of cannabis as their primary motivation. Under Schedule I, cannabis was federally classified as having no medical value, a designation that many commenters—including patients and healthcare providers—argued was inconsistent with real-world medical practice and state-level legalizations.
Economic factors also weighed heavily. Approximately 27.8% of supporters pointed to the growth of legal cannabis industries and the potential for increased state tax revenue. Others highlighted the need for criminal justice reform, noting that federal prohibition continues to result in racial disparities in arrests and prevents individuals from accessing housing or employment due to past convictions.
Health Risks and Opposition Concerns
While the majority favored reform, the 6.7% who opposed any change raised significant public health concerns. Opponents focused on the risks of dependence, the impact on adolescent brain development, and the potential for impaired driving.
Some experts worry that moving cannabis to a lower schedule might send a “misleading message” about its safety. “Public enthusiasm for cannabis as medicine needs to be matched by federal and state investment in rigorous cannabis research,” said Ryan Vandrey, Ph.D., a cannabis researcher and professor of psychiatry and behavioral sciences at Johns Hopkins University.
Public health authorities emphasize that cannabis use is not without risk:
-
Adolescents: Brain development continues until age 25, and early use is linked to higher rates of addiction and cognitive impairment.
-
Pregnancy: THC can cross the placenta, potentially leading to lower birth weights and developmental issues.
-
Mental Health: High-potency THC products are associated with an increased risk of psychosis, particularly in those with a family history of mental health disorders.
What This Means for Research and Patients
For the scientific community, the shift to Schedule III is a major breakthrough. For decades, the “Schedule I” designation created a “catch-22”: researchers could not prove the medical benefits of cannabis because the classification made it nearly impossible to obtain the drug for clinical trials.
“The classification of cannabis as a Schedule I drug made it very difficult to perform rigorous, controlled studies,” explained Mark Ilgen, Ph.D., an addiction psychologist at the University of Michigan. “Rescheduling opens the door to conducting these crucial studies and could greatly improve the quality of advice given to individuals.”
For patients, the change may eventually lead to better product standards and more reliable clinical evidence. However, it is important to note that Schedule III does not mean “over-the-counter.” Products must still undergo FDA approval to be marketed as medicines.
Policy vs. Science: A Growing Gap
The study highlights a significant challenge for lawmakers: public opinion and state-level commerce are moving much faster than federal science and regulation. While many Americans view cannabis as a benign or helpful substance, clinicians warn that the current “wild west” of state markets lacks the rigorous oversight found in traditional pharmacy-grade medications.
As the DEA moves toward a permanent, comprehensive rescheduling hearing set for June 2026, the data from this study will likely serve as a cornerstone of the administrative record.
“Rescheduling improves conditions at the margins—research becomes more accessible and operators see tax relief—but it doesn’t address the structural issues,” noted experts involved in the study. Issues like interstate commerce, banking access, and federal adult-use policy remain unresolved.
Study Limitations
The researchers noted that while the scale of the data is historic, public comments are not a perfectly representative sample of the entire U.S. population. Individuals who take the time to submit comments to Regulations.gov are often more motivated or politically engaged than the average citizen. Therefore, the findings should be viewed as a snapshot of the engaged public rather than a definitive national poll.
References
- https://www.earth.com/news/most-americans-support-the-reclassification-of-cannabis-believing-reform-should-go-even-further/
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
